The first module is held by the oncologist Aleix Prat
December 18, 2020 – After last year's success, the second edition of the Specialization course in Precision Medicine in the treatment of tumors. The 2019-2020 edition has reached about 1.000 members from all over the country (health professionals, students and postgraduates), obtaining the continuity of training meetings despite the health emergency due to Covid-19. Also in this new edition there is a training method with flexible teaching (part time and blended) after lThe high level of satisfaction seen by last year's webinar courses and remote methodology.
Land practical applications of the use of diagnostics in the field of neoplastic pathologies and the theoretical and practical bases for the identification, characterization and diagnosis of pathologies and the bases of oncological treatment, are once again the protagonists of this path.
The course was born from the training need to combine the skills of the pathologist with those of the oncologist to form i precision medicine professionals in ochnology, with the aim of finding the right tumor market for the correct oncological therapy. The 9 thematic modules in the program are based on these foundations; each includes two master readings, one on the oncological aspects and one on the anatomopathological aspects, which will frame the specific theme. Furthermore, for each module there is a discussion session and analysis of clinical cases aimed at reinforcing the acquisition of the knowledge learned. The Specialization Course will then be completed by 5 monographic sessions, of which three sessions held by international experts (in English) and two sessions held by the Scientific Directors of the course.
The initiation form is about the breast cancer, tissue markers and precision oncology, held by the internationally renowned oncologist Aleix Prat. Head of the Department of Medical Oncology at Hospital Clinic Barcelona (Spain), associate professor at the University of Barcelona, Prat is Head of the Translational Genomics and Targeted Therapy in Solid Tumors (IDIBAPS) group. Throughout his career he has achieved worldwide prestige as a researcher in the field of breast cancer genomics and biomarker development, has received competitive funding from several sources including the Government of Spain and various other funding organizations such as the Susan G. Komen Foundation. Since 2007 he has actively participated in more than 200 publications, 38 as 1st author and 18 as senior author and 13.479 citations.
>> Click here for all the information on the specialization course